Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pharmacovigilance Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Market Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pharmacovigilance Market Analysis and Forecast, 2017-2028
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. COVID-19 Impact on the Pharmacovigilance Market
• 5.2. Technological Advancements (big data analytics, cloud-based database, automation)
• 5.3. Drugs Regulatory Framework of Pharmacovigilance Market
• 5.4. Pharmacovigilance Market: Value Chain Analysis
• 5.5. Pharmacovigilance Market: Porter's Five Forces Analysis
• 5.6. Overview of Drugs Adverse Effects

6. Global Pharmacovigilance Market Analysis and Forecast, by Phase of Drug Development

• 6.1. Introduction & Definition
  • 6.1.1. Key Findings / Developments
• 6.2. Global Pharmacovigilance Market Value Forecast, by Phase of Drug Development, 2017-2028
  • 6.2.1. Preclinical Studies
  • 6.2.2. Phase I
  • 6.2.3. Phase II
  • 6.2.4. Phase III
  • 6.2.5. Phase IV or Post Marketing Surveillance
• 6.3. Global Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028

7. Global Pharmacovigilance Market Analysis and Forecast, by Type of Method

• 7.1. Introduction & Definition
  • 7.1.1. Key Findings / Developments
• 7.2. Global Pharmacovigilance Market Value Forecast, by Type of Method, 2017-2027
  • 7.2.1. Spontaneous Reporting
  • 7.2.2. Intensified ADR Reporting
  • 7.2.3. Targeted Spontaneous Reporting
  • 7.2.4. Cohort Event Monitoring
  • 7.2.5. EHR Mining
• 7.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method,2021-2028

8. Global Pharmacovigilance Market Analysis and Forecast, by Type of Service

• 8.1. Introduction & Definition
  • 8.1.1. Key Findings / Developments
• 8.2. Global Pharmacovigilance Market Value Forecast, by Type of Service, 2017-2027
  • 8.2.1. In-house
  • 8.2.2. Contract Outsourcing
• 8.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028

9. Global Pharmacovigilance Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Global Pharmacovigilance Market Value Forecast, by Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. North America Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028

10. North America Pharmacovigilance Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
  • 10.2.1. Preclinical Studies
  • 10.2.2. Phase I
  • 10.2.3. Phase II
  • 10.2.4. Phase III
  • 10.2.5. Phase IV or Post Marketing Surveillance
• 10.3. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
  • 10.3.1. Spontaneous Reporting
  • 10.3.2. Intensified ADR Reporting
  • 10.3.3. Targeted Spontaneous Reporting
  • 10.3.4. Cohort Event Monitoring
  • 10.3.5. EHR Mining Others
• 10.4. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
  • 10.4.1. In-house
  • 10.4.2. Contract Outsourcing
• 10.5. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. North America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
  • 10.6.1. By Phase of Drug Development
  • 10.6.2. By Type of Method
  • 10.6.3. By Type of Service
  • 10.6.4. By Country

11. Europe Pharmacovigilance Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
  • 11.2.1. Preclinical Studies
  • 11.2.2. Phase I
  • 11.2.3. Phase II
  • 11.2.4. Phase III
  • 11.2.5. Phase IV or Post Marketing Surveillance
• 11.3. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
  • 11.3.1. Spontaneous Reporting
  • 11.3.2. Intensified ADR Reporting
  • 11.3.3. Targeted Spontaneous Reporting
  • 11.3.4. Cohort Event Monitoring
  • 11.3.5. EHR Mining
• 11.4. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
  • 11.4.1. In-house
  • 11.4.2. Contract Outsourcing
• 11.5. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Spain
  • 11.5.5. Italy
  • 11.5.6. Rest of Europe
• 11.6. Europe Pharmacovigilance Market Attractiveness Analysis, 2021-2028
  • 11.6.1. By Phase of Drug Development
  • 11.6.2. By Type of Method
  • 11.6.3. By Type of Service
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Pharmacovigilance Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
  • 12.2.1. Preclinical Studies
  • 12.2.2. Phase I
  • 12.2.3. Phase II
  • 12.2.4. Phase III
  • 12.2.5. Phase IV or Post Marketing Surveillance
• 12.3. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
  • 12.3.1. Spontaneous Reporting
  • 12.3.2. Intensified ADR Reporting
  • 12.3.3. Targeted Spontaneous Reporting
  • 12.3.4. Cohort Event Monitoring
  • 12.3.5. EHR Mining
• 12.4. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
  • 12.4.1. In-house
  • 12.4.2. Contract Outsourcing
• 12.5. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Asia Pacific Pharmacovigilance Market Attractiveness Analysis, 2021-2028
  • 12.6.1. By Phase of Drug Development
  • 12.6.2. By Type of Method
  • 12.6.3. By Type of Service
  • 12.6.4. By Country/Sub-region

13. Latin America Pharmacovigilance Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
  • 13.2.1. Preclinical Studies
  • 13.2.2. Phase I
  • 13.2.3. Phase II
  • 13.2.4. Phase III
  • 13.2.5. Phase IV or Post Marketing Surveillance
• 13.3. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
  • 13.3.1. Spontaneous Reporting
  • 13.3.2. Intensified ADR Reporting
  • 13.3.3. Targeted Spontaneous Reporting
  • 13.3.4. Cohort Event Monitoring
  • 13.3.5. EHR Mining
• 13.4. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
  • 13.4.1. In-house
  • 13.4.2. Contract Outsourcing
• 13.5. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
  • 13.6.1. By Phase of Drug Development
  • 13.6.2. By Type of Method
  • 13.6.3. By Type of Service
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Pharmacovigilance Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017-2027
  • 14.2.1. Preclinical Studies
  • 14.2.2. Phase I
  • 14.2.3. Phase II
  • 14.2.4. Phase III
  • 14.2.5. Phase IV or Post Marketing Surveillance
• 14.3. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017-2027
  • 14.3.1. Spontaneous Reporting
  • 14.3.2. Intensified ADR Reporting
  • 14.3.3. Targeted Spontaneous Reporting
  • 14.3.4. Cohort Event Monitoring
  • 14.3.5. EHR Mining
• 14.4. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017-2027
  • 14.4.1. In-house
  • 14.4.2. Contract Outsourcing
• 14.5. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, 2021-2028
  • 14.6.1. By Phase of Drug Development
  • 14.6.2. By Type of Method
  • 14.6.3. By Type of Service
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (by tier and size of companies)
• 15.2. Market Share / Position Analysis, by Company, 2020
• 15.3. Competitive Business Strategies
• 15.4. Company Profiles
  • 15.4.1. Accenture plc
    • 15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.1.2. Phase of Drug Development Portfolio
    • 15.4.1.3. Financial Overview
    • 15.4.1.4. Strategic Overview
    • 15.4.1.5. SWOT Analysis
  • 15.4.2. Bristol-Myers Squibb
    • 15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.2.2. Phase of Drug Development Portfolio
    • 15.4.2.3. Financial Overview
    • 15.4.2.4. Strategic Overview
    • 15.4.2.5. SWOT Analysis
  • 15.4.3. Clinquest Group B.V.
    • 15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.3.2. Phase of Drug Development Portfolio
    • 15.4.3.3. Financial Overview
    • 15.4.3.4. Strategic Overview
    • 15.4.3.5. SWOT Analysis
  • 15.4.4. Cognizant
    • 15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.4.2. Phase of Drug Development Portfolio
    • 15.4.4.3. Financial Overview
    • 15.4.4.4. Strategic Overview
    • 15.4.4.5. SWOT Analysis
  • 15.4.5. Labcorp Drug Development
    • 15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.5.2. Phase of Drug Development Portfolio
    • 15.4.5.3. Financial Overview
    • 15.4.5.4. Strategic Overview
    • 15.4.5.5. SWOT Analysis
  • 15.4.6. F. Hoffmann-La Roche Ltd.
    • 15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.6.2. Phase of Drug Development Portfolio
    • 15.4.6.3. Financial Overview
    • 15.4.6.4. Strategic Overview
    • 15.4.6.5. SWOT Analysis
  • 15.4.7. GlaxoSmithKline plc
    • 15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.7.2. Phase of Drug Development Portfolio
    • 15.4.7.3. Financial Overview
    • 15.4.7.4. Strategic Overview
    • 15.4.7.5. SWOT Analysis
  • 15.4.8. ICON plc
    • 15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.8.2. Phase of Drug Development Portfolio
    • 15.4.8.3. Financial Overview
    • 15.4.8.4. Strategic Overview
    • 15.4.8.5. SWOT Analysis
  • 15.4.9. iGATE Corporation
    • 15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.9.2. Phase of Drug Development Portfolio
    • 15.4.9.3. Financial Overview
    • 15.4.9.4. Strategic Overview
    • 15.4.9.5. SWOT Analysis
  • 15.4.10. iMEDGlobal Corporation
    • 15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.10.2. Phase of Drug Development Portfolio
    • 15.4.10.3. Strategic Overview
    • 15.4.10.4. SWOT Analysis
  • 15.4.11. Syneos Health
    • 15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.11.2. Phase of Drug Development Portfolio
    • 15.4.11.3. Financial Overview
    • 15.4.11.4. Strategic Overview
    • 15.4.11.5. SWOT Analysis
  • 15.4.12. Novartis AG
    • 15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.12.2. Phase of Drug Development Portfolio
    • 15.4.12.3. Financial Overview
    • 15.4.12.4. Strategic Overview
    • 15.4.12.5. SWOT Analysis
  • 15.4.13. PAREXEL International Corporation
    • 15.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.13.2. Phase of Drug Development Portfolio
    • 15.4.13.3. Financial Overview
    • 15.4.13.4. Strategic Overview
    • 15.4.13.5. SWOT Analysis
  • 15.4.14. Pfizer, Inc.
    • 15.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.14.2. Phase of Drug Development Portfolio
    • 15.4.14.3. Financial Overview
    • 15.4.14.4. Strategic Overview
    • 15.4.14.5. SWOT Analysis
  • 15.4.15. Pharmaceutical Phase of Drug Development, LLC. (PPD)
    • 15.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.15.2. Phase of Drug Development Portfolio
    • 15.4.15.3. Financial Overview
    • 15.4.15.4. Strategic Overview
    • 15.4.15.5. SWOT Analysis
  • 15.4.16. IQVIA
    • 15.4.16.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.16.2. Phase of Drug Development Portfolio
    • 15.4.16.3. Financial Overview
    • 15.4.16.4. Strategic Overview
    • 15.4.16.5. SWOT Analysis
  • 15.4.17. Sanofi
    • 15.4.17.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.17.2. Phase of Drug Development Portfolio
    • 15.4.17.3. Financial Overview
    • 15.4.17.4. Strategic Overview
    • 15.4.17.5. SWOT Analysis
  • 15.4.18. Synowledge LLC
    • 15.4.18.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.18.2. Phase of Drug Development Portfolio
    • 15.4.18.3. Strategic Overview
    • 15.4.18.4. SWOT Analysis
  • 15.4.19. Wipro Limited
    • 15.4.19.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.4.19.2. Phase of Drug Development Portfolio
    • 15.4.19.3. Financial Overview
    • 15.4.19.4. Strategic Overview
    • 15.4.19.5. SWOT Analysis

List of Tables

• Table 01: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
• Table 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
• Table 03: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
• Table 04: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Region, 2017-2028
• Table 05: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
• Table 06: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
• Table 07: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
• Table 08: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country, 2017-2028
• Table 09: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
• Table 10: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
• Table 11: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
• Table 12: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
• Table 13: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
• Table 14: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
• Table 15: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
• Table 16: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
• Table 17: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
• Table 18: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
• Table 19: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
• Table 20: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028
• Table 21: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017-2028
• Table 22: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017-2028
• Table 23: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017-2028
• Table 24: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2028

List of Figures

• Figure 01: Pharmacovigilance Market Snapshot
• Figure 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2027
• Figure 03: Market Value Share, by Phase of Drug Development, 2018
• Figure 04: Market Value Share, by Type of Service, 2018
• Figure 05: Market Value Share, by Region, 2018
• Figure 06: Global Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
• Figure 07: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Preclinical Studies, 2017-2028
• Figure 08: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase I, 2017-2028
• Figure 09: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase II, 2017-2028
• Figure 10: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase III, 2017-2028
• Figure 11: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Phase IV or Post Marketing Surveillance, 2017-2028
• Figure 12: Global Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Phase of Drug Development
• Figure 13: Global Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
• Figure 14: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), Spontaneous Reporting, 2017-2028
• Figure 15: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intensified ADR Reporting, 2017-2028
• Figure 16: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Spontaneous Reporting, 2017-2028
• Figure 17: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cohort Event Monitoring, 2017-2028
• Figure 18: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EHR Mining, 2017-2028
• Figure 19: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2028
• Figure 20: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
• Figure 21: Global Pharmacovigilance Market Value Share Analysis, by Type of Service Providers, 2020 and 2028
• Figure 22: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by In-house, 2017-2028
• Figure 23: Global Pharmacovigilance Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Outsourcing, 2017-2028
• Figure 24: Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
• Figure 25: Global Pharmacovigilance Market Value Share Analysis, by Region, 2020 and 2028
• Figure 26: Global Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028
• Figure 27: North America Pharmacovigilance Market Size (US$ Mn) Forecast, 2017-2028
• Figure 28: North America Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028
• Figure 29: North America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
• Figure 30: North America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
• Figure 31: North America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
• Figure 32: North America Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028
• Figure 33: North America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
• Figure 34: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
• Figure 35: North America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
• Figure 36: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, 2017-2028
• Figure 37: Europe Pharmacovigilance Market Attractiveness Analysis, by Country, 2021-2028
• Figure 38: Europe Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
• Figure 39: Europe Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
• Figure 40: Europe Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
• Figure 41: Europe Pharmacovigilance Market Value Share Analysis, by Country, 2020 and 2028
• Figure 42: Europe Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
• Figure 43: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
• Figure 44: Europe Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
• Figure 45: Asia Pacific Pharmacovigilance Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017- 2028
• Figure 46: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Country 2021-2028
• Figure 47: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
• Figure 48: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
• Figure 49: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
• Figure 50: Asia Pacific Pharmacovigilance Market Value Share Analysis, by Country, 2018 and 2027
• Figure 51: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
• Figure 52: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
• Figure 53: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
• Figure 54: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2028
• Figure 55: Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028, by Country/Sub-region, 2021-2028
• Figure 56: Latin America Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
• Figure 57: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
• Figure 58: Latin America Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
• Figure 59: Latin America Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
• Figure 60: Latin America Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
• Figure 61: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
• Figure 62: Latin America Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
• Figure 63: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, 2017-2028
• Figure 64: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Country/Sub-region, 2021-2028
• Figure 65: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Phase of Drug Development, 2020 and 2028
• Figure 66: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Method, 2020 and 2028
• Figure 67: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Type of Service, 2020 and 2028
• Figure 68: Middle East & Africa Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2020 and 2028
• Figure 69: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
• Figure 70: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Method, 2021-2028
• Figure 71: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
• Figure 72: Global Pharmacovigilance Market Share Analysis, by Company (2020)